FibroGen, Inc (FGEN) CEO Sells $1,036,287.00 in Stock
FibroGen, Inc (NASDAQ:FGEN) CEO Thomas B. Neff sold 18,900 shares of FibroGen stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $54.83, for a total transaction of $1,036,287.00. Following the completion of the transaction, the chief executive officer now directly owns 3,176,861 shares in the company, valued at approximately $174,187,288.63. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Shares of FibroGen, Inc (NASDAQ:FGEN) traded down 0.45% during mid-day trading on Wednesday, hitting $55.05. 371,377 shares of the stock were exchanged. The stock’s market capitalization is $3.92 billion. FibroGen, Inc has a 12-month low of $15.60 and a 12-month high of $60.15. The stock’s 50 day moving average price is $52.02 and its 200-day moving average price is $36.39.
FibroGen (NASDAQ:FGEN) last announced its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.01). The company had revenue of $29.00 million for the quarter, compared to analyst estimates of $34.80 million. FibroGen had a negative return on equity of 64.42% and a negative net margin of 105.59%. On average, equities research analysts expect that FibroGen, Inc will post ($1.81) EPS for the current fiscal year.
Several hedge funds have recently made changes to their positions in FGEN. Ameritas Investment Partners Inc. acquired a new stake in shares of FibroGen during the 1st quarter worth approximately $111,000. Quantbot Technologies LP acquired a new stake in FibroGen in the 2nd quarter valued at $128,000. SG Americas Securities LLC grew its position in FibroGen by 6.5% in the 2nd quarter. SG Americas Securities LLC now owns 6,747 shares of the biopharmaceutical company’s stock valued at $218,000 after purchasing an additional 412 shares during the period. Amalgamated Bank acquired a new stake in FibroGen in the 2nd quarter valued at $237,000. Finally, BNP Paribas Arbitrage SA grew its position in FibroGen by 589.1% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 7,401 shares of the biopharmaceutical company’s stock valued at $239,000 after purchasing an additional 6,327 shares during the period. 47.49% of the stock is owned by institutional investors.
A number of brokerages have weighed in on FGEN. Leerink Swann reaffirmed an “outperform” rating and issued a $82.00 price target (up previously from $52.00) on shares of FibroGen in a research note on Tuesday, August 8th. William Blair reaffirmed an “outperform” rating on shares of FibroGen in a research note on Wednesday, August 9th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $75.00 price target on shares of FibroGen in a research note on Tuesday, August 8th. Citigroup Inc. lifted their price target on shares of FibroGen from $48.00 to $65.00 and gave the company a “top pick” rating in a research note on Tuesday, August 8th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $38.00 price target (up previously from $32.00) on shares of FibroGen in a research note on Thursday, June 22nd. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. FibroGen currently has a consensus rating of “Buy” and a consensus target price of $65.67.
FibroGen Company Profile
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Stock Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related stocks with our FREE daily email newsletter.